264 related articles for article (PubMed ID: 9627118)
21. Mutant p53 proteins have diverse intracellular abilities to oligomerize and activate transcription.
Miller CW; Chumakov A; Said J; Chen DL; Aslo A; Koeffler HP
Oncogene; 1993 Jul; 8(7):1815-24. PubMed ID: 8510927
[TBL] [Abstract][Full Text] [Related]
22. Difference in the centrosome duplication regulatory activity among p53 'hot spot' mutants: potential role of Ser 315 phosphorylation-dependent centrosome binding of p53.
Tarapore P; Tokuyama Y; Horn HF; Fukasawa K
Oncogene; 2001 Oct; 20(47):6851-63. PubMed ID: 11687964
[TBL] [Abstract][Full Text] [Related]
23. Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity.
Notterman D; Young S; Wainger B; Levine AJ
Oncogene; 1998 Nov; 17(21):2743-51. PubMed ID: 9840938
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional properties of feline p53 and its tumour-associated mutants: a yeast-based approach.
Cardellino U; Ciribilli Y; Andreotti V; Modesto P; Menichini P; Fronza G; Pellegrino C; Inga A
Mutagenesis; 2007 Nov; 22(6):417-23. PubMed ID: 17947339
[TBL] [Abstract][Full Text] [Related]
25. Analysis of transactivation capability and conformation of p53 temperature-dependent mutants and their reactivation by amifostine in yeast.
Grochova D; Vankova J; Damborsky J; Ravcukova B; Smarda J; Vojtesek B; Smardova J
Oncogene; 2008 Feb; 27(9):1243-52. PubMed ID: 17724467
[TBL] [Abstract][Full Text] [Related]
26. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
Willis A; Jung EJ; Wakefield T; Chen X
Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
[TBL] [Abstract][Full Text] [Related]
27. The N terminus of the murine p53 tumour suppressor is an independent regulatory domain affecting activation and thermostability.
Hansen S; Lane DP; Midgley CA
J Mol Biol; 1998 Jan; 275(4):575-88. PubMed ID: 9466932
[TBL] [Abstract][Full Text] [Related]
28. p53 transactivation through various p53-responsive elements.
Park DJ; Chumakov AM; Miller CW; Pham EY; Koeffler HP
Mol Carcinog; 1996 Jun; 16(2):101-8. PubMed ID: 8645424
[TBL] [Abstract][Full Text] [Related]
29. Influence of promoter DNA topology on sequence-specific DNA binding and transactivation by tumor suppressor p53.
Kim E; Rohaly G; Heinrichs S; Gimnopoulos D; Meissner H; Deppert W
Oncogene; 1999 Dec; 18(51):7310-8. PubMed ID: 10602486
[TBL] [Abstract][Full Text] [Related]
30. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity.
Unger T; Sionov RV; Moallem E; Yee CL; Howley PM; Oren M; Haupt Y
Oncogene; 1999 May; 18(21):3205-12. PubMed ID: 10359526
[TBL] [Abstract][Full Text] [Related]
31. The DNA binding activity of wild type p53 is modulated by blocking its various antigenic epitopes.
Wolkowicz R; Elkind NB; Ronen D; Rotter V
Oncogene; 1995 Mar; 10(6):1167-74. PubMed ID: 7535417
[TBL] [Abstract][Full Text] [Related]
32. Abrogation of wild-type p53-mediated transactivation is insufficient for mutant p53-induced immortalization of normal human mammary epithelial cells.
Cao Y; Gao Q; Wazer DE; Band V
Cancer Res; 1997 Dec; 57(24):5584-9. PubMed ID: 9407971
[TBL] [Abstract][Full Text] [Related]
33. Selection of cell death-deficient p53 mutants in Saccharomyces cerevisiae.
Yacoubi-Hadj Amor I; Smaoui K; Belguith H; Djemal L; Dardouri M; Mokdad-Gargouri R; Gargouri A
Yeast; 2009 Aug; 26(8):441-50. PubMed ID: 19579214
[TBL] [Abstract][Full Text] [Related]
34. Mutations of tumor necrosis factor alpha-responsive serine residues within the C-terminal transactivation domain of human transcription factor REL enhance its in vitro transforming ability.
Starczynowski DT; Reynolds JG; Gilmore TD
Oncogene; 2005 Nov; 24(49):7355-68. PubMed ID: 16027730
[TBL] [Abstract][Full Text] [Related]
35. Localization of a mutant p53 response element on the tissue inhibitor of metalloproteinase-3 promoter: mutant p53 activities are distinct from wild-type.
Thomas S; Reisman D
Cancer Lett; 2006 Aug; 240(1):48-59. PubMed ID: 16236433
[TBL] [Abstract][Full Text] [Related]
36. p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles.
Rand A; Glenn KS; Alvares CP; White MB; Thibodeau SM; Karnes WE
Cancer Lett; 1996 Jan; 98(2):183-91. PubMed ID: 8556707
[TBL] [Abstract][Full Text] [Related]
37. Hetero-oligomerization does not compromise 'gain of function' of tumor-derived p53 mutants.
Deb D; Scian M; Roth KE; Li W; Keiger J; Chakraborti AS; Deb SP; Deb S
Oncogene; 2002 Jan; 21(2):176-89. PubMed ID: 11803461
[TBL] [Abstract][Full Text] [Related]
38. Effects of p51/p63 missense mutations on transcriptional activities of p53 downstream gene promoters.
Kato S; Shimada A; Osada M; Ikawa S; Obinata M; Nakagawara A; Kanamaru R; Ishioka C
Cancer Res; 1999 Dec; 59(23):5908-11. PubMed ID: 10606233
[TBL] [Abstract][Full Text] [Related]
39. CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity.
Tanner S; Barberis A
J Negat Results Biomed; 2004 Nov; 3():5. PubMed ID: 15548325
[TBL] [Abstract][Full Text] [Related]
40. Specific DNA binding by different classes of human p53 mutants.
Rolley N; Butcher S; Milner J
Oncogene; 1995 Aug; 11(4):763-70. PubMed ID: 7651740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
